Having trouble viewing this email? View in your browser.
ESCMID Logo

22 May 2018
WEEKLY NEWS

Dear colleagues,

Communications Manager Chantal Britt will leave ESCMID at the end of this month after more than three years at the society. We thank Chantal for all her hard work and commitment and wish her all the best in her career. You may send all communication requests to the dedicated email address communication@escmid.org.

Your ESCMID communications editors

 

Conference on antimicrobial resistance from 26 – 28 September 2018 in Cuba

The registration is now open for the conference on antimicrobial resistance from bench to practice, which takes place in Havana, Cuba, from 26 – 28 September 2018. Latin America is a hotbed for many well-known and emerging infectious diseases. It is also a region that contributes greatly to both the global spread of and the cultural debate on antimicrobial resistance. This conference aims to bring together local scientists and renowned international experts to address this important global health issue. It targets clinical microbiologists, as well as infectious disease and public health specialists. ESCMID co-organises the conference with Sociedad Cubana de Microbiología y Parasitología, Asociación panamericana de Infectología, Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica, and The Lancet Infectious Diseases.

› Read more
 

CMI highlight: review of patient-related determinants of antibiotic use

Zanicelli et al assessed patient-related determinants potentially influencing antibiotic use. They included 87 studies from 33 countries in their systematic review. Seventy-five were quantitative and described self-reported, objectively assessed or self-reported and objectively assessed patient-related determinants. Twelve were qualitative studies or had a qualitative and quantitative component. Eighty-six studies concerned the outpatient setting. They identified seven broad categories of determinants having an impact on different aspects of antibiotic use (in descending order of frequency): demographic and socio/economic characteristics, patient-doctor interactions (e.g. counselling), treatment characteristics (e.g. administration frequency), attitudes (e.g. expecting antibiotics), access to treatment (e.g. patients’ direct costs), characteristics of the condition for which the antibiotic was prescribed (e.g. duration of symptoms), knowledge (e.g. regarding indications for treatment). Most determinants were classified as “barriers” to responsible antibiotic use. The authors concluded that a large variety of patient-related determinants impact antibiotic use. The most easily “modifiable” determinants concern patient-doctor interactions, treatment characteristics and knowledge. Data from the inpatient setting and low- and middle-income countries were underrepresented.

› Read more
 

ECDC publishes 2016 laboratory capabilities and capacity report

The European Centre for Disease Prevention and Control published the 2016 EULabCap report, which on an annual basis assesses key public health microbiology capabilities and capacities for surveillance and epidemic preparedness in the European Union and the European Economic Area. This fourth report shows continuing progress of the capacities across the European clinical and public health community in diagnosing and monitoring infection and antimicrobial resistance for health protection. The average EULabCap 2016 index for all EU/EEA countries was 7.5 on a scale of 0–10, the same as in 2015 and higher than the 7.3 in 2014, and 6.9 in 2013. The ECDC also publishes interactive capacity maps by country. Individual EULabCap indices per country ranged from 5.6 to 9.6 as compared to 4.7 to 9.2 in 2013, indicating that differences between national systems gradually decreased from 2013 to 2016. Ten countries improved their EULabCap index; five climbed from low to fair, and another five countries went from fair to high. The goal of the survey is to ascertain how well microbiology laboratories are equipped to detect, assess and monitor infectious disease threats. The results help policymakers at all levels identify possible areas for action and evaluate the impact of capacity strengthening activities and health system reform.

› Read more
ESCMID Executive Office
P.O. Box 214
4010 Basel
Switzerland
Phone +41 61 5080 173
info@escmid.org
www.escmid.org
Follow ESCMID
Visit us on LinkedIn Visit us on YouTube
 
The ESCMID Newsletter is issued on behalf of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) by the ESCMID Executive Office. It contains announcements of ESCMID-related matters and other information of interest to professionals in the infection field.

Tip: To ensure that you receive the ESCMID newsletter in your inbox, add newsletter@escmid.org to your email program’s address book.

You have received this email as a contact of ESCMID or one of its affiliated societies. You can unsubscribe or change your newsletter subscriptions here.